Hervolution Therapeutics develops immunotherapies targeting tumors using Human Endogenous Retroviral proteins (HERVs).
Hervolution Therapeutics has raised $11.7M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Hervolution Therapeutics's investors include European Innovation Council, Serum Institute of India Pvt. Ltd..
Hervolution Therapeutics is headquartered in Copenhagen, Denmark.
Hervolution Therapeutics develops immunotherapies targeting tumors using Human Endogenous Retroviral proteins (HERVs).
Hervolution Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hervolution Therapeutics — Funding & Investors." VCBacked, December 19, 2024, https://www.vcbacked.co/company/hervolution-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Hervolution Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hervolution-therapeutics
{{cite web |title=Hervolution Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/hervolution-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated